Volume 12, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


First I wish to thank the participants for their excellent presentations.

It was suggested that the chairman provide a brief summary of the Symposium. I have chosen to do this in the form of a reply to a hypothetical question raised by a health officer and phrased as follows: “What new or improved immunoprophylactic procedures will be ready in the reasonably near future for my use in the prevention of arbovirus diseases of man?”

The aforementioned health officer should be encouraged by the progress being made toward the development of vaccines against several specific infections, and by the accumulation of basic information on approaches that might lead to induction of broad immunity against a wide spectrum of arboviruses. However, none of the vaccines or potential vaccines described today will be available as a commercially produced, licensed vaccine within a year.

The inactivated Rift Valley fever vaccine prepared by Dr. Randall and his associates from monkey-kidney tissue cultures, by techniques analogous to those developed for manufacturing safe Salk vaccine, is potent and safe in animals and man.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...


Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error